IMPAX Laboratories, Inc. Launches Authorized Generic RENVELA
RENVELA is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
Trending on the Topix Network
Impax Laboratories Receives New Coverage from Analysts at Sterne Agee
Other equities research analysts have also recently issued reports about the stock.
Fri Apr 11, 2014
Bay Area's IMPAX Laboratories, Inc. Tries Again With Once-Rebuffed Parkinson's Drug Rytary
IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug for the symptomatic treatment of Parkinson's disease .
Tue Apr 08, 2014
Health Care Sector Stocks under Review -- Research on Sanofi, Impax...
The Dow Jones Industrial Average finished at 16,245.87, down 1.02%. During the session, nine out of ten sectors ended the session in negative.
Mon Apr 07, 2014
IMPAX Laboratories, Inc. Schedules Conference Call And Webcast For...
The Company will host a conference call and live webcast with the investment community at The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site, www.impaxlabs.com .
Wed Apr 02, 2014
Customer Interaction Solutions
Impax Laboratories Inc Files (8-K) Disclosing Change in Directors or...
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Impax Laboratories Names Leader of Technical Operations
Impax Laboratories today announced that Jeffrey D. Nornhold has been appointed Senior Vice President, Technical Operations and will oversee the Company's manufacturing, supply chain, quality and technical operations.
Wed Mar 19, 2014
Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel...
The gains were broad based as nine out of ten sectors ended the session in positive.